[{"orgOrder":0,"company":"Qunol","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Coenzyme Q10","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Qunol","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Qunol \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Qunol \/ Sanofi"},{"orgOrder":0,"company":"Qunol","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Coenzyme Q10","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Qunol","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Qunol \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Qunol \/ Sanofi"},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for (+-)-alpha-Tocopherol

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : LPCN 2401, an oral proprietary combination of anabolic androgen receptor agonist (Testosterone Undecanoate) and α-tocopherol, an antioxidant, is being investigated for the treament of obesity.

                          Brand Name : LPCN 2401

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 11, 2024

                          Lead Product(s) : Testosterone Undecanoate,Vitamin E

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Qunol

                          Country arrow
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Qunol

                          Country arrow
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the US.

                          Brand Name : Qunol CoQ10

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 29, 2023

                          Lead Product(s) : Coenzyme Q10,Vitamin E

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Sanofi

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          03

                          Qunol

                          Country arrow
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Qunol

                          Country arrow
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the U.S.

                          Brand Name : Qunol CoQ10

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 27, 2023

                          Lead Product(s) : Coenzyme Q10,Vitamin E

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Sanofi

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank